|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1400 Crystal Drive |
Address2 | Suite 300 |
| City | Arlington |
State | VA |
Zip Code | 22202 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 46803-12
|
||||||||
|
6. House ID# 343580000
|
||||||||
| TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Dorothy Farrell |
Date | 7/3/2019 10:25:49 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
SENATE/HOUSE - FY 2020 Raise the Caps
Signed onto letter addressed to Congress urging to raise the cap on domestic and international discretionary spending for fiscal years 2020 and 2021. Failure to raise the caps will result in sharply reduced funding for domestic and international discretionary programs (together known as non-defense or NDD) from $597 billion in FY 2019 to $543 billion in FY 2020, a $54 billion drop, or 9 percent, not counting inflation.
SENATE - FY20 Labor, Health and Human Services, and Education and Related Agencies Appropriations Request
Singed onto bill led by the CDC Coalition addressed to Sen. Blunt and Sen. Murray urging the Senate to match the $8.22 billion provided to CDC programs in the HOUSE FY 2020 Labor, Health and Human Services, and Education, and Related Agencies bill totaling $225 million from the HHS Nonrecurring Expenses Fund.
HOUSE - IHS Health Workforce
Signed onto letter led by the AI/AN Health Partners group to House Interior Appropriations committee requesting improved funding for the IHS Health Workforce.
BUD - HHS - Letter to Secretary Azar on Fetal Tissue
Signed onto letter led by International Society for Stem Cell Research to Secretary Azar voicing opposition to new policies on research using human fetal tissue announced by HHS.
HOUSE - H.R. 2021 Investing for People Act of 2019
Officially endorsed H.R. 2021 Investing for People Act of 2019 introduced by Representative John Yarmuth to increase discretionary spending limits and increases both defense and nondefence discretionary spending limits for FY20 and FY21.
HOUSE - H.R. 2741 LIFT America Act
Signed onto letter in support of H.R. 2741 the Leading Infrastructure for Tomorrows (LIFT) America Act introduced by House Democrats of the Energy and Commerce committee.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dorothy |
Farrell |
|
|
|
Jasey |
Cardenas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
SENATE - DREAM Act S. 874
Signed onto letter lead by the Health Professionals Coalition addressed to Sens. McConnell, Schumer, Graham, Feinstein urging the Senate to adopt H.R. 6 the Dream and Promise Act passed by the House of Representatives or to pass S. 874 the Dream Act a similar measure introduced by Senators Graham and Durbin.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jasey |
Cardenas |
|
|
|
Dorothy |
Farrell |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
SENATE - Public Health Funding Restoration Act
Worked with Senator Richard Blumenthal (D-CT) on supporting the introduction of the Public Health Restoration Act and signed on as a supporting organization.
ADMINISTRATION - Letter to White House, OMB, POTUS and HHS Opposing FDA Guidance
Signed onto letter led by Friends of Cancer research to the Administration, Mick Mulvaney, Russel Vought, Trump and Alexander Azar voicing opposition to FDA guidance documents.
SENATE - Cannabidiol and Marijuana Research Expansion Act
Signed letter led by American Psychological Association addressed to Senate leaders asking for the reintroduction of the Cannabidiol and Marijuana Research Expansion Act.
HOUSE - Rep. Buddy Carter Amendment Rec. to H.R. 987 Strengthening Healthcare and Lowering Prescription Drug Cost Act
Contacted by Rep. Buddy Carters office regarding amendment to H.R. 987 Strengthening Healthcare and Lower Prescription Drug Cost Act which included provision regarding outreach to colleges of pharmacy by the Secretary of HHS and Education with respect to materials related to generic drugs and biosimilar.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dorothy |
Farrell |
|
|
|
Jasey |
Cardenas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Status of pharmacists as health care providers for Medicare/Medicaid services
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dorothy |
Farrell |
|
|
|
Jasey |
Cardenas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |